Recombinant DLL4 (Navicixizumab Biosimilar) antibody
This Human Monoclonal antibody specifically detects DLL4 (Navicixizumab Biosimilar) in BLI, ELISA, FACS, Func and SPR. It exhibits reactivity toward Human.
Catalog No. ABIN7675739
$346.15
Plus shipping costs $50.00
Shipping to:
United States
Delivery in 10 to 12 Business Days
Quick Overview for Recombinant DLL4 (Navicixizumab Biosimilar) antibody (ABIN7675739)
Target
DLL4 (Navicixizumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Human
Clonality
Monoclonal
Application
Bio-Layer Interferometry (BLI), ELISA, Flow Cytometry (FACS), Functional Studies (Func), Surface Plasmon Resonance (SPR)
-
-
Expression System
- CHO Cells
-
Purpose
- Anti-DLL4 Reference Antibody (navicixizumab)
-
Characteristics
- Anti-DLL4 Reference Antibody (navicixizumab) is expressed from CHO. The heavy chain type is huIgG2, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
Purity
- >95 %
-
Isotype
- IgG2SA
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Storage
- 4 °C,-80 °C
-
Storage Comment
- +4°C,-80°C
-
-
- DLL4 (Navicixizumab Biosimilar)
-
Target Type
- Biosimilar
-
Molecular Weight
- 145.5 kDa
-
UniProt
- Q9NR61
Target
-
You are here:
